Literature DB >> 10906713

Immunohistochemical evidence for the involvement of protein convertases 5A and 2 in the processing of pro-neurotensin in rat brain.

P Villeneuve1, L Lafortune, N G Seidah, P Kitabgi, A Beaudet.   

Abstract

The neuropeptides/neurotransmitters neurotensin (NT) and neuromedin (NN) are synthesized by endoproteolytic cleavage of a common inactive precursor, pro-NT/NN. In vitro studies have suggested that the prohormone convertases PC5A and PC2 might both be involved in this process. In the present study, we used dual immunohistochemical techniques to determine whether either one or both of these two convertases were co-localized with pro-NT/NN maturation products and could therefore be involved in the physiological processing of this propeptide in rat brain. PC2-immunoreactive neurons were present in all regions immunopositive for NT. All but three regions expressing NT were also immunopositive for PC5A. Dual localization of NT with either convertase revealed that NT was extensively co-localized with both PC5A and PC2, albeit with regional differences. These results strongly suggest that PC5A and PC2 may play a key role in the maturation of pro-NT/NN in mammalian brain. The regional variability in NT/PC co-localization patterns may account for the region-specific maturation profiles previously reported for pro-NT/NN. The high degree of overlap between PC5A and PC2 in most NT-rich areas further suggests that these two convertases may act jointly to process pro-NT/NN. At the subcellular level, PC5A was largely co-localized with the mid-cisternae Golgi marker MG-160. By contrast, PC2 was almost completely excluded from MG-160-immunoreactive compartments. These results suggest that PC5A, which is particularly efficient at cleaving the two C-terminal-most dibasics of pro-NT/NN, may be acting as early as in the Golgi apparatus to release NT, whereas PC2, which is considerably more active than PC5A in cleaving the third C-terminal doublet, may be predominantly involved further distally along the secretory pathway to release NN. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10906713     DOI: 10.1002/1096-9861(20000828)424:3<461::aid-cne5>3.0.co;2-j

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  6 in total

Review 1.  The role of neurotensin in central nervous system pathophysiology: what is the evidence?

Authors:  Fannie St-Gelais; Claudia Jomphe; Louis-Eric Trudeau
Journal:  J Psychiatry Neurosci       Date:  2006-07       Impact factor: 6.186

Review 2.  Prohormone convertases differentially process pro-neurotensin/neuromedin N in tissues and cell lines.

Authors:  Patrick Kitabgi
Journal:  J Mol Med (Berl)       Date:  2006-05-11       Impact factor: 4.599

3.  Laser-capture microdissection and transcriptional profiling of the dorsomedial nucleus of the hypothalamus.

Authors:  Syann Lee; Angie L Bookout; Charlotte E Lee; Laurent Gautron; Matthew J Harper; Carol F Elias; Bradford B Lowell; Joel K Elmquist
Journal:  J Comp Neurol       Date:  2012-11-01       Impact factor: 3.215

4.  RNAi-mediated silencing of prohormone convertase (PC) 5/6 expression leads to impairment in processing of cocaine- and amphetamine-regulated transcript (CART) precursor.

Authors:  Jeffrey Stein; Rohan Shah; Donald F Steiner; Arunangsu Dey
Journal:  Biochem J       Date:  2006-11-15       Impact factor: 3.857

5.  HMC-1 human mast cells synthesize neurotensin (NT) precursor, secrete bioactive NT-like peptide(s) and express NT receptor NTS1.

Authors:  David E Cochrane; Robert E Carraway; Kimberly Harrington; Melissa Laudano; Stephen Rawlings; Ross S Feldberg
Journal:  Inflamm Res       Date:  2011-09-17       Impact factor: 4.575

6.  Attenuation of insulin signalling contributes to FSN-1-mediated regulation of synapse development.

Authors:  Wesley L Hung; Christine Hwang; Shangbang Gao; Edward H Liao; Jyothsna Chitturi; Ying Wang; Hang Li; Christian Stigloher; Jean-Louis Bessereau; Mei Zhen
Journal:  EMBO J       Date:  2013-05-10       Impact factor: 11.598

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.